Home / Top News / Arbutus Announces Robust HBsAg Decline Data with AB-729 Dosed at 60 mg Every 8 Weeks in Chronic Hepatitis B Subjects
Arbutus Announces Robust HBsAg Decline Data with AB-729 Dosed at 60 mg Every 8 Weeks in Chronic Hepatitis B Subjects
Repeat dosing of 60 mg AB-729 every
8 to AB-729 dosed every 4 weeks
(
AB-729 remains generally safe and well tolerated with no SAEs or treatment discontinuations in any cohort
WARMINSTER, Pa., Dec. 10, 2020 (GLOBE NEWSWIRE) Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection as well as therapies to treat coronaviruses (including COVID-19), today announced additional clinical data from an ongoing Phase 1a/1b clinical trial (AB-729-001) with AB-729, its proprietary GalNAc delivered RNAi compound.